@aserritella.bsky.social
In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is :
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection
www.nejm.org/doi/full/10....
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection
www.nejm.org/doi/full/10....
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism | NEJM
In patients with active cancer and venous thromboembolism, whether extended treatment
with a reduced dose of an oral anticoagulant is effective in preventing recurrent
thromboembolic events and dec...
www.nejm.org
March 30, 2025 at 10:40 AM
In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is :
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection
www.nejm.org/doi/full/10....
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection
www.nejm.org/doi/full/10....
Excited to join Bluesky
November 25, 2024 at 3:45 AM
Excited to join Bluesky